Bristol-Myers Squibb, Celgene slide following news of delayed deal and psoriasis drug divestment

FAN Editor

Giovanni Caforio, CEO of Bristol-Meyers Squibbs

Adam Jeffery | CNBC

Shares of Bristol-Meyers Squibb fell 7% Monday after the pharmaceutical giant announced that the proposed acquisition of Celgene will now close later than originally expected and will involve a divestiture of Celgene’s psoriasis drug.

In a Securities and Exchange Commission filing, the company said it now expects to close the planned $74 billion deal by the end of 2019 or beginning of 2020. It had originally expected to close the acquisition by the third quarter.

Celgene’s stock also dropped 5%.

Bristol-Meyers Squibb said that the divestiture of the drug Otezla would be used to help the company decrease financial leverage after the merger. Otezla generated about $1.6 billion in revenue last fiscal year for Celgene, according to a securities filing.

Bristol-Meyers Squibb announced the acquisition in January but has not yet received approval from the Federal Trade Commission.

“Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene. The company is focused on realizing the promise of the transaction, and is continuing to work to complete the transaction on a timely basis,” the company said in a securities filing.

Shareholders of both companies had previously approved the deal.

Free America Network Articles

Leave a Reply

Next Post

Pilot killed in Eurofighter collision over eastern Germany

A forest offcial stands next do debris after two Eurofighter warplanes crashed after a mid-air collision near the village of Jabel in northeastern Germany June 24, 2019 REUTERS/Petra Konermann/Nordkurier June 24, 2019 BERLIN (Reuters) – One pilot was killed and another managed to parachute to safety after two unarmed German […]